Name | NANOFARMA DEVELOPMENT, OOO |
|---|
INN | 1655283577 |
|---|
KPP | 165801001 |
|---|
OGRN | 1131690091158 |
|---|
OKPO | 34741564 |
|---|
Address | 420095, Respublika Tatarstan (tatarstan), g. Kazan', ul. Vosstaniya, d. D. 102V |
|---|
Phone | +7 (8432) 12-54-90 |
|---|
|
| OKVED code | Type | Name of activity type |
|---|
| 21.20 | Core activity | Manufacturers of drugs and pharmaceuticals and medical products | | 10.89 | Additional activity | Manufacture of other food products nec | | 10.89.1 | Additional activity | Production of soups and broths | | All types of activities | | 10.89.5 | Additional activity | Manufacture of artificial honey and caramel | | 10.89.6 | Additional activity | Honey Processing (tempering, filtration, mixing honey and decrystallization) | | 10.89.7 | Additional activity | Manufacture of food rations and rations | | 10.89.8 | Additional activity | Production of biologically active food additives | | 10.89.9 | Additional activity | Manufacture of other food products, not included in other categories | | 46.46 | Additional activity | Wholesale of pharmaceutical goods | | 47.73 | Additional activity | Retailing drugs in specialized stores (pharmacies) | | 72.19 | Additional activity | Research and experimental development on natural sciences and engineering Other |
Registration date | 31.12.2013 |
|---|
|
NANOFARMA DEVELOPMENT, OOO (Tatarstan, Republic; INN 1655283577) was registered on 31 Dec 2013. The company's authorized capital as of July 1, 2012 was 131760000 rub. Principal activities of NANOFARMA DEVELOPMENT, OOO: manufacturers of drugs and pharmaceuticals and medical products (21.20), manufacture of other food products nec (10.89), production of soups and broths (10.89.1). |
Economic indicators2023
Net profit (RAS) of NANOFARMA DEVELOPMENT, OOO made up 101.56 million RUB over 2023 compared to net loss of 60.27 million RUB over 2022, the company informed. Revenue increased in the accounting period 1.72 times to 628.42 million RUB from 366.17 million RUB over 2022; cost of goods sold decreased by 1.51% to 238.66 million RUB from 242.33 million RUB; sales profit made up 220.15 million RUB compared to sales loss of 17.54 million RUB. 2022
Net loss (RA) of NANOFARMA DEVELOPMENT, OOO made up 60.27 million RUB over 2022 compared to net profit of 12.50 million RUB over 2021, the company informed. Revenue decreased in the accounting period by 5.44% to 366.17 million RUB from 387.25 million RUB in 2021; cost of goods sold grew by 22.79% to 242.33 million RUB from 197.36 million RUB; sales loss made up 17.54 million RUB compared to sales profit of 44.54 million RUB. 2021
Net profit (RAS) of NANOFARMA DEVELOPMENT, OOO dropped in 2021 5.34 times to 12.50 million RUB from 66.71 million RUB over the same period in 2020, the company informed. Revenue decreased in the accounting period by 27.20% to 387.25 million RUB from 531.90 million RUB in 2020; cost of goods sold grew by 13.67% to 197.36 million RUB from 173.62 million RUB; sales profit fell 5.25 times to 44.54 million RUB from 233.77 million RUB. 2020
Net profit (RAS) of NANOFARMA DEVELOPMENT, OOO grew over 2020 2.02 times to 66.71 million RUB from 33.07 million RUB over 2019, the company informed. Revenue increased in the accounting period 1.70 times to 531.90 million RUB from 313.46 million RUB over 2019; cost of goods sold grew 1.93 times to 173.62 million RUB from 90.16 million RUB; sales profit went up 2.66 times to 233.77 million RUB from 87.99 million RUB. 2019
Net profit (RAS) of NANOFARMA DEVELOPMENT, OOO made up 36.98 million RUB over 2019 compared to net loss of 80.00 million RUB over 2018, the company informed. Revenue increased in the accounting period 7.87 times to 346.47 million RUB from 44.03 million RUB over 2018; cost of goods sold grew 2.83 times to 90.16 million RUB from 31.86 million RUB; sales profit made up 92.88 million RUB compared to sales loss of 49.23 million RUB. 2018
Net loss (RAS) of NANOFARMA DEVELOPMENT, OOO increased 2.40 times to 80.00 million RUB from 33.32 million RUB over 2017, the company informed. Revenue decreased in the accounting period by 13.93% to 44.03 million RUB from 51.15 million RUB in 2017; cost of goods sold decreased by 8.61% to 31.86 million RUB from 34.86 million RUB; sales loss grew by 49.94% to 49.23 million RUB from 32.84 million RUB. 2017
Net loss (RAS) of NANOFARMA DEVELOPMENT, OOO increased by 2.65% to 33.32 million RUB from 32.46 million RUB over 2016, the company informed. Sales loss decreased by 4.14% to 32.84 million RUB from 34.25 million RUB. 2016
Net loss (RAS) of NANOFARMA DEVELOPMENT, OOO increased 3.06 times to 32.46 million RUB from 10.60 million RUB over 2015, the company informed. Sales loss grew 2.41 times to 34.25 million RUB from 14.23 million RUB. 2014
unlimited access to database "Kontragent" download any information within 24 hours
Companies in the region
|